Are batroxobin agents effective for perioperative hemorrhage in thoracic surgery? A systematic review of randomized controlled trials
Authors:
- Pingping XiaoPXPingping Xiao
- Junmin ChenJCJunmin Chen
- Yisheng WeiYWYisheng Wei
- 1 March 2009
- journal article
- research article
- Published by Wolters Kluwer Health in Blood Coagulation & Fibrinolysis
- Vol. 20 (2) , 101-107
Abstract
The objective of the present study was to evaluate the effect of batroxobin agents on perioperative hemorrhage in thoracic surgery.We systematically searched Cochrane Library, Pubmed, EMBASE and the China Biological Medicine CD-ROM Databases up to August 2007. Reference lists of all included studies and of reviews related to the topic of the present systematic review were manually searched. Two reviewers independently identified the eligible studies, assessed their methodological quality and extracted data. Results of relevant outcomes were pooled together whenever possible, using RevMan software.Five randomized controlled trials involving 678 patients were included. Three trials were for pneumonectomy and two for cardiac surgery with cardiopulmonary bypass. The quality of the identified studies was generally poor. All the trials claimed randomized allocation, but allocation concealment was unclear. Blinding was not mentioned. Two trials found that batroxobin agents decreased intraoperative blood loss for pneumonectomy. Mean differences between the batroxobin agents group and the no-treatment group were -182.20 ml [95% confidence interval (CI), -207.48 to -156.92] and -131.32 ml (95% CI, -142.95 to -119.69), respectively, for these two trials. All included trials reported less drainage volume favoring the batroxobin agents group. Mean differences at different time points after operation ranged from -15 ml (95% CI, -31.77 to 1.77) to -150.60 ml (95% CI, -179.26 to -121.94). Although most of the differences between the batroxobin agents group and the no treatment group were statistically significant, clinical value was limited.There is not enough evidence supporting any benefit of batroxobin agents for hemorrhage during thoracic surgery.Keywords
This publication has 11 references indexed in Scilit:
- Feasibility of treating hyperfibrinogenemia with intermittently administered batroxobin in patients with ischemic stroke/transient ischemic attack for secondary preventionBlood Coagulation & Fibrinolysis, 2007
- The Potential of Bothrops moojeni Venom in the Field of HemostasisPathophysiology of Haemostasis and Thrombosis, 2005
- Defibrinogenating effect of batroxobin (Defibrase®) in rats and inhibition of migration of human vascular smooth muscle cells by the plasma of batroxobin-treated rats in vitroAtherosclerosis, 2001
- Snake venom proteases affecting hemostasis and thrombosisBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 2000
- Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statementThe Lancet, 1999
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- Empirical Evidence of BiasJAMA, 1995
- Plasma levels and urinary excretion of batroxobin and its defibrinogenating effects in various animal species.The Journal of Toxicological Sciences, 1986
- The influence of snake venom enzymes on blood coagulationPharmacology & Therapeutics, 1985
- [18] The coagulant enzyme from Bothrops atrox venom (batroxobin)1976